1 – 4 of 4
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA) : results from a double-blind, phase 3, randomised controlled trial
(
- Contribution to journal › Article
- 2017
-
Mark
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
(
- Contribution to journal › Article
- 2016
-
Mark
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
(
- Contribution to journal › Article